AbCellera Biologics Inc. (ABCL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AbCellera Biologics Inc. (ABCL) closed at USD 12.37 on 2026-10-14, a change of +119.7 % over the past year, with a market capitalization of USD 4.11B.

AbCellera Biologics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AbCellera Biologics Inc. key figures

Previous close

USD 12.37 (2026-10-14)

1-year change

+119.7 %

Market cap

USD 4.11B

Enterprise value

USD 3.48B

P/E ratio (trailing)

-23.48

P/E ratio (forward)

-16.63

EPS (trailing)

-0.54

EPS (forward)

-0.76

PEG ratio

n/a

Price to book

4.34

Revenue growth

-76.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.04

Employees

562

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AbCellera Biologics Inc. and compare it with other stocks.